This article just skims the surface. Here is more useful information: Rapamycin modulates activity of two related and key molecular complexes that have partly

This article just skims the surface. Here is more useful information: Rapamycin modulates activity of two related and key molecular complexes that have partly disjoint action. Health benefits and longevity are mainly associated with inhibition of the mTOR-C1 complex using a low or intermediate and often intermittent dose of rapamycin or other rapalogs (for example. see work of Dudley Lamming and Matt Kaeberlein in PubMed.) Inhibition of the mTOR-C2 requires somewhat higher rapamycin levels and may be required for transplant patients. But persistent mTOR-C2 inhibition is apparently the main cause of adverse outcomes. Most self-experimentation involve one or two oral doses in the range 0.2 to 0.6 mg every 5 to 10 days. This intermittent dosing will cause mTOR-C1 activity to oscillate in what users or their physicians hopes is a range without adverse immune suppression due to excessive drug action. Experimental work in mice indicates that initiation of treatment later in life is effective in health gains and lifespan, although not as effective as match treatment initiated earlier in adults. Short duration treatment of three months in mice (~5 years in human) is also somewhat effective, but again less so than longer term treatment. For graphs of survival curves of different treatments of genetically heterogeneous mice (by sex) see the impressive data of the Interventional Testing Program funded by NIH’s National Institute on Aging. https://phenome.jax.org/projects/ITP1 https://phenome.jax.org/projects/ITP1